Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant

Nassim Kamar; Florence Abravanel; Olivier Marion; Raphaelle Romieu-Mourez; Chloé Couat; Arnaud Del Bello; Jacques Izopet

doi:10.1001/jamanetworkopen.2021.36030

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant

JAMA Netw Open. 2021 Nov 1;4(11):e2136030. doi: 10.1001/jamanetworkopen.2021.36030.

Authors

Nassim Kamar^{1

2

3}, Florence Abravanel^{2

3

4}, Olivier Marion^{1

2

3}, Raphaelle Romieu-Mourez⁴, Chloé Couat¹, Arnaud Del Bello^{1

3}, Jacques Izopet^{2

3

4}

Affiliations

¹ Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France.
² Université Paul Sabatier, Toulouse, France.
³ Toulouse Institute for Inflammatory and Infectious Diseases (Infinity), Inserm, French National Centre for Scientific Research, Toulouse, France.
⁴ Department of Virology, Toulouse University Hospital, Toulouse, France.

Abstract

This case series study assesses whether a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)–based vaccine is associated with improved anti–SARS-CoV-2 antibody response in solid organ transplant recipients in France.

MeSH terms

Adult
Antibodies, Viral / blood
Antibodies, Viral / immunology*
COVID-19 / immunology*
COVID-19 Vaccines / therapeutic use*
Female
Humans
Male
Middle Aged
Organ Transplantation*
SARS-CoV-2 / immunology*
Transplant Recipients*

Substances

Antibodies, Viral
COVID-19 Vaccines